TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33369253
Drug: Leg heat
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leg heat therapy (HT)
Study: 32892987
Drug: Single Antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Antiplatelet Therapy (SAPT)
Study: 34910278
Drug: Dual Antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Antiplatelet Therapy (DAPT)
Study: 34142951
Drug: Generic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic metformin hydrochloride (850 mg)
Study: 34142951
Drug: Glucophage (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucophage (reference preparation)
Study: 32076783
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) treatment
Study: 32564889
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy followed by preoperative chemotherapy and surgery
Study: 32464334
Drug: 4-valent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-valent HPV vaccine (6/11/16/18)
Study: 36431312
Drug: Conventional NEURO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional NEURO® occupational therapy
Study: 32053984
Drug: Walnut group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut group (1, 1.5, or 2 oz. of walnuts daily)
Study: 35438586
Drug: Integrated Behavior
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Behavior Therapy for Children with Selective Mutism (IBTSM)
Study: 32451241
Drug: ACTitouch adaptive
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTitouch adaptive compression therapy (ACT) system
Study: 34491021
Drug: Kynurenic acid
Normalized name: Kynurenic Acid
DrugBank: Kynurenic Acid (DB11937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kynurenic acid 0.5% (FS2) cream (Group 1)
Study: 34491021
Drug: Active onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active onion extract comparator treatment (Group 2)
Study: 32026257
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 0 ng·ml‐1
Study: 32026257
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 1 ng·ml‐1
Study: 32026257
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 3 ng·ml‐1
Study: 32026257
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 5 ng·ml‐1
Study: 32050055
Drug: Naltrexone HCl
Normalized name: naltrexone HCl
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone HCl (10 mg)
Study: 32050055
Drug: Nalmefene HCl
Normalized name: nalmefene HCl
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nalmefene HCl (10 mg)
Study: 36277907
Drug: Pimavanserin 34
Normalized name: pimavanserin 34 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin 34 mg
Study: 33773103
Drug: Buprenorphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine plus naloxone therapy
Study: 33539760
Drug: Referral for
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral for methadone maintenance therapy
Study: 35717608
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR)
Study: 34951474
Drug: Warrior Programme
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warrior Programme intervention (Time Line Therapy™)
Study: 32888826
Drug: 2.5mg inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg inhaled lancovutide (once daily, every other day or twice a week) for eight weeks
Study: 33472052
Drug: Catheter ablation-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter ablation-based AF rhythm control with optimal HF therapy and aggressive catheter ablation (PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug)
Study: 33472052
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control with optimal HF therapy and measures to achieve resting HR < 80 bpm and 6-minute walk HR < 110 bpm
Study: 35029187
Drug: antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: antihypertensive drugs + acupuncture
Study: 35029187
Drug: antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: antihypertensive drugs + sham acupuncture
Study: 33773580
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (40 mg.kg−1 bolus and 20 mg.kg−1.h−1 infusion)
Study: 33773580
Drug: Lidocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (3 mg.kg−1 bolus and 3 mg.kg−1.h−1 infusion)
Study: 33773580
Drug: Magnesium plus
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium plus lidocaine (equal doses of both drugs)
Study: 33773580
Drug: Control (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isotonic solution)
Study: 32564649
Drug: SHARe program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHARe program (weekly eight-session, 12-hour group program)
Study: 33169490
Drug: Unguided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided Internet-based cognitive-behavioral therapy (iCBT)
Study: 36460266
Drug: Family-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Based Treatment (FBT-ARFID)
Study: 36460266
Drug: Psychoeducational Motivation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational Motivation Therapy (PMT)
Study: 33244458
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg/d
Study: 34758252
Drug: Sacubitril-valsartan (97
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily)
Study: 32259228
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus Olaratumab (75 mg/m2 + 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles)
Study: 32259228
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus Placebo (75 mg/m2 + placebo)
Study: 37102974
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics
Study: 34480008
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB; 0.3 g/kg body mass) with high-intensity (HI) warm-up
Study: 34480008
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB; 0.3 g/kg body mass) with low-intensity (LI) warm-up
Study: 36148560
Drug: Hypothetical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical treatment to reduce exacerbation rate
Study: 32144167
Drug: Smart bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart bolus calculator informed by real-time insulin sensitivity estimates
Study: 35401774
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment (PT)
Study: 35918696
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic (IA)
Study: 32109991
Drug: Fixed-Dose Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Dose Combination (FDC) of amlodipine/losartan/rosuvastatin 5/100/20 mg
Study: 32109991
Drug: Loose Combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose Combination (LC) of amlodipine/losartan and rosuvastatin
Study: 32486256
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil capsules (2 g per day, 860 mg DHA + 120 mg EPA)
Study: 32658503
Drug: Active Neurofeedback
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Neurofeedback Training (NFT), 24 sessions, twice a week
Study: 36529811
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus topical corticosteroids
Study: 36384746
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (telmisartan 40 mg/day)
Study: 34664527
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg/day for 12 weeks
Study: 34950221
Drug: Xiaoyutang combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoyutang combined with intraperitoneal heat perfusion chemotherapy
Study: 34950221
Drug: Intraperitoneal thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal thermal perfusion chemotherapy (Control)
Study: 38956594
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg psilocybin
Study: 36322843
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg psilocybin
Study: 36322843
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg psilocybin (control)
Study: 34701532
Drug: GC4711 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC4711 (100 mg IV prior to each of 5 consecutive daily SBRT fractions of 10-12Gy)
Study: 34701532
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in the Phase 2 cohort concurrent with SBRT)
Study: 35766657
Drug: Atazanavir, Daclatasvir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir, Daclatasvir, or Sofosbuvir (in combination)
Study: 32833476
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to cancer control behaviors and treatment compliance
Study: 33432635
Drug: Medication Overuse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication Overuse Treatment Strategy trial
Study: 33432635
Drug: Migraine preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine preventive medication
Study: 35951066
Drug: Reiki therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reiki therapy (21 sessions)
Study: 32348605
Drug: Intra-articular methylprednisolone
Normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular methylprednisolone acetate (MPA) 100 mg/joint
Study: 32348605
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone acetate (MPA) 200 mg
Study: 36278451
Drug: Recovery-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery-focused therapy plus treatment as usual
Study: 32101269
Drug: ICG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG group (laparoscopic gastrectomy using near‐infrared imaging after endoscopic peritumoral injection of ICG 1 day before surgery)
Study: 36891906
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy
Study: 34143234
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia (IAA) with sevoflurane treatment
Study: 34143234
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia (IVA) with propofol treatment
Study: 33284679
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg/d for 3 days followed by 200 mg/d for 11 days)
Study: 33284679
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (500 mg/d followed by 250 mg/d) as a placebo‐equivalent control
Study: 32498269
Drug: Porphyra tenera
Normalized name: Porphyra tenera extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks
Study: 32498269
Drug: Placebo (crystal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (crystal cellulose capsules) for 8 weeks
Study: 32498269
Drug: Porphyra tenera
Normalized name: Porphyra tenera extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks (subgroup analysis of 101 subjects without URI)
Study: 37573352
Drug: In-centre nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In-centre nocturnal haemodialysis (INHD), 6 to 8 hours thrice-weekly for 6 months
Study: 37573352
Drug: Conventional haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 hours per session)
Study: 34407342
Drug: Adjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant pembrolizumab (200 mg intravenously once every 3 weeks for up to 17 cycles)
Study: 32427795
Drug: Health Empowerment
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Empowerment Intervention (HEI) consisting of 6 weekly sessions based on the Health Empowerment Theory
Study: 32319791
Drug: Conventional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy
Study: 33862045
Drug: HIC (Hepatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIC (Hepatic Insulin Clearance)
Study: 33156995
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (metronidazole cream)
Study: 33156995
Drug: 0.56% MTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56% MTZ cream (negative control)
Study: 33156995
Drug: 0.95% MTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.95% MTZ cream (negative control)
Study: 33156995
Drug: 0.75% MTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% MTZ cream
Study: 32311911
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of the β2‐agonist salbutamol
Study: 32648391
Drug: Herb-separated moxibustion
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herb-separated moxibustion at Jinsuo (GV 8)-eight-diagram points, applied for 40 min once daily for 8 weeks.
Study: 32648391
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide tablets, 50 mg three times a day for 8 weeks.
Study: 32648391
Drug: Tongxieyaofang decoction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxieyaofang decoction, one dose a day for 8 weeks, taken separately in two times.
Study: 34666302
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg three times a day for 10 days
Study: 33600687
Drug: Inhaled Human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Human Insulin (Exubera®)
Study: 33600687
Drug: Subcutaneous Insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Insulin
Study: 33753352
Drug: High-dose 24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 24-hour infusion of tranexamic acid
Study: 33536398
Drug: Pemafibrate 0.025-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.025-0.2 mg BID
Study: 34665865
Drug: LD-RTX monotherapy
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-RTX monotherapy
Study: 36333954
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid (5-mg intravenously)
Study: 35978361
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block (FICB) administered by paramedics
Study: 33499025
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g β-Lactoglobulin (BLG)
Study: 33499025
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g Whey Protein Isolate (WPI)
Study: 34105063
Drug: Intramuscular paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular paromomycin monotherapy (20 mg/kg for 21 days) in African patients
Study: 34105063
Drug: Intramuscular paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular paromomycin monotherapy (15 mg/kg for 21 days) in Indian patients
Study: 34105063
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (15 mg/kg for 17 days with sodium stibogluconate) in African patients
Study: 35947046
Drug: Oxytocin receptor
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin receptor antagonists
Study: 33947690
Drug: Veliparib throughout
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib throughout (240 mg BID for 14 days, then 400 mg BID maintenance)
Study: 33947690
Drug: Veliparib combination
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib combination only (240 mg BID for 14 days, then placebo)
Study: 33947690
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo plus chemotherapy followed by placebo)
Study: 33947690
Drug: Veliparib combination
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib combination only
Study: 36524387
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Study: 35027302
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with inhaled lavender essential oil (n = 30)
Study: 32584996
Drug: Alendronate after
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate after stopping treatment
Study: 32314290
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora extract 10 mg/kg/day (Z10)
Study: 32314290
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora extract 5 mg/kg/day (Z5)
Study: 36474755
Drug: EP-104IAR (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-104IAR (15 mg)
Study: 35120193
Drug: Antioxidants (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (3 g IV vitamin C and 100 mg/kg N‐acetylcysteine)
Study: 32406210
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT), 8.3 ± 2 sessions
Study: 32412700
Drug: Esketamine 84
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 84 mg nasal spray twice-weekly for 4 weeks + standard-of-care treatment
Study: 32412700
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray twice-weekly for 4 weeks + standard-of-care treatment
Study: 35085482
Drug: Rectal indometacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indometacin (100 mg) administered 30 min before ESWL
Study: 35085482
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical glycerin suppositories) administered 30 min before ESWL
Study: 35085482
Drug: Rectal indometacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indometacin (100 mg)
Study: 35085482
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical glycerin suppositories)
Study: 37769545
Drug: Controlled-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbamazepine (CBZ-CR)
Study: 32381496
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) at 3 L·kg‐1·min‐1
Study: 32381496
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (Control)
Study: 32785213
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg BNT162b1
Study: 32785213
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg BNT162b1
Study: 35092241
Drug: Multidisciplinary approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary approach to treatment
Study: 35092241
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy regimen
Study: 34813489
Drug: Videoconference-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconference-based cognitive behavioral therapy (vCBT)
Study: 33051240
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cell (DC) vaccines
Study: 33051240
Drug: Extracellular/soluble ICOSL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracellular/soluble ICOSL released from vaccine DCs
Study: 35756871
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with atorvastatin calcium tablets (20 mg/d for 15 days), traditional Chinese medicine (TCM) decoctions, and acupuncture therapy once daily for 15 days.
Study: 35756871
Drug: Atorvastatin calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin calcium tablets (20 mg/d for 15 days)